Orthofix Medical announced the publication of the five-year results from the U.S. clinical study comparing the M6-C artificial cervical disc with anterior cervical discectomy and fusion ACDF. Published in The Spine Journal, patients treated with the M6-C disc demonstrated superior clinical success at 60 months compared to ACDF patients. Secondary findings indicated significant improvements in neck and arm pain, function, and quality of life scores. The M6-C patient group maintained the flexion-extension and lateral bending motion reported at earlier time points. The publication of this data coincides with the recognition that more than 100,000 implantations of the M6-C artificial cervical disc and the M6-L artificial lumbar disc (only available outside the U.S.) have been performed worldwide since the product’s first introduction in 2006.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OFIX:
- Orthofix names Massimo Calafiore President and CEO
- Orthofix price target lowered to $14 from $16 at Stifel
- Orthofix Medical cuts FY23 revenue view to $739M-$744M, consensus $754.63M
- Orthofix Medical reports Q3 adjusted EPS 7c, consensus (21c)
- Orthofix International (OFIX) Q3 Earnings Cheat Sheet
Questions or Comments about the article? Write to editor@tipranks.com